Opendata, web and dolomites

ReMedPsy SIGNED

Re-emerging Magic Molecules: The Medicalization of Psychedelics in the United States

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 ReMedPsy project word cloud

Explore the words cloud of the ReMedPsy project. It provides you a very rough idea of what is the project "ReMedPsy" about.

abuse    placed    yield    1960s    country    science    model    scientists    psilocybin    mental    evaluations    co    began    imaginaries    scientific    policy    lsd    coming    addiction    actors    restrictive    psychiatric    psychedelic    responsible    traces    sociotechnical    benefit    2000    see    slowly    researcher    complete    insights    training    forefront    culture    highlighting    regulations    revival    molecules    standstill    center    controversial    changed    introduction    decades    methodology    recommendations    constellations    ptsd    policies    political    health    actor    substances    explores    transfer    integration    enabled    qualitative    governments    risk    society    interplay    ketamine    re    threat    1930s    public    contemporary    indicated    frame    career    nor    fostered    treating    deepen    60s    drug    significantly    sts    licensed    mdma    western    regard    almost    medicines    category    accepted    psychedelics    depression    socio    again    classifications    investigates    medical    ascribing   

Project "ReMedPsy" data sheet

The following table provides information about the project.

Coordinator
UNIVERSITAT WIEN 

Organization address
address: UNIVERSITATSRING 1
city: WIEN
postcode: 1010
website: www.univie.ac.at

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Austria [AT]
 Total cost 261˙208 €
 EC max contribution 261˙208 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2017
 Funding Scheme MSCA-IF-GF
 Starting year 2018
 Duration (year-month-day) from 2018-08-01   to  2021-07-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSITAT WIEN AT (WIEN) coordinator 261˙208.00
2    PRESIDENT AND FELLOWS OF HARVARD COLLEGE US (CAMBRIDGE) partner 0.00

Map

 Project objective

This proposal presents a research-via-training project that will transfer knowledge from the U.S. to Europe and allow the experienced researcher to deepen her study of (re-)emerging scientific fields to advance her career significantly. The project explores how scientists and other actors currently re-frame psychedelics in a scientific model to make them into licensed medicines. Since their introduction into Western science and culture (1930s-60s), psychedelic substances such as psilocybin or LSD have been highly controversial. Although early research indicated promising psychiatric applications, Western governments began to see psychedelics as a threat to public health in the 1960s and placed them into the most restrictive drug category, ascribing them a high potential for abuse and no currently accepted medical use. After coming to an almost complete standstill for several decades, psychedelic research is slowly re-emerging since 2000, highlighting again their potential for treating mental health issues such as addiction, depression, or PTSD. Since neither the molecules nor regulations have changed, this project investigates which socio-political conditions have enabled this revival (e.g., changes in the scientific or broader culture, risk-benefit evaluations). It traces how the responsible re-integration of psychedelics is fostered through the interplay of actor constellations, the production of scientific knowledge, and sociotechnical imaginaries. Using a qualitative research methodology and approaches from Science and Technology Studies (STS), it focuses on three molecules that are at the center of contemporary research in the U.S. (the country currently at the forefront of psychedelic research): MDMA, psilocybin, and ketamine. The project results will yield important insights into how psychedelic science and society are co-produced, and provide timely policy recommendations with regard to drug classifications, and drug and public health policies.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "REMEDPSY" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "REMEDPSY" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

ToMComputations (2019)

How other minds are represented in the human brain: Neural computations underlying Theory of Mind

Read More  

FOCUSIS (2020)

Focal volume Control Using Structured Illumination Sources

Read More  

MingleIFT (2020)

Multi-color and single-molecule fluorescence imaging of intraflagellar transport in the phasmid chemosensory cilia of C. Elegans

Read More